Administrative Core

MARCE联盟促进有助于美国人民国防的研究。 生物威胁，包括故意释放生物恐怖制剂和自然杀伤人员地雷。 传染病的出现或重新出现。作为其正式定义的使命的一部分，MARCE还 保持与中大西洋地区公共卫生当局的互动，以便在需要时， 该联盟可以调动其技术资源，协助该地区的公共卫生当局， 大规模或不寻常的疾病爆发、假定的生物恐怖事件或其他灾难。马克 拟议在2009-2014年供资周期（MARCE-2）成立一个财团， 来自27个研究机构的科学家将参与一系列合作研究项目（ 其中绝大多数代表跨越机构边界的合作）。Myron M.博士 Levine，医学博士，DTPH，Grollman杰出教授和疫苗中心主任 发展马里兰州大学医学院，将继续担任校长 调查员和主任的MARCE。艾莉森奥布莱恩博士，博士，教授和系主任 健康科学统一服务大学的微生物学，将继续担任共同， 首席研究员。第A4节中的图4-1提供了MARCE-2的组织结构图。

The MARCE consortium fosters research that contributes to the defense of the population of the United States of America against biological threats including the deliberate release of bioterror agents and the natural emergence or re-emergence of infectious diseases. As part of its formally defined mission, the MARCE also maintains interactions with public health authorities within the Middle Atlantic Region so that if the need arises, the consortium can mobilize its technical resources to assist the region's public health authorities in the face of a large or unusual outbreak of disease, presumed bioterror incident or other catastrophe. The MARCE consortium that is proposed for the funding cycle of 2009-2014 (MARCE-2) encompasses approximately 65 scientists from 27 research institutions who will engage in a series of collaborative research projects (the vast majority of which represent collaborations that extend across institutional boundaries). Dr. Myron M. Levine, M.D., D.T.P.H., the Grollman Distinguished Professor and Director of the Center for Vaccine Development of the University of Maryland School of Medicine, will continue to serve as the Principal Investigator and Director of the MARCE. Dr. Alison O'Brien, Ph.D., Professor and Chair of the Department of Microbiology of the Uniformed Services University of the Health Sciences, will continue to serve as Co- Principal Investigator. Figure 4-1 in Section A4 provides an overview organizational chart of MARCE-2.